Boehringer Ingelheim

1 article

Pharmaceutical scientist analyzing molecular data, representing the complex balance between drug efficacy and patient tolerability in obesity treatment.

Boehringer's obesity drug shows efficacy, faces tolerability challenge

In a pivotal Phase 3 obesity trial, 19% of patients on Boehringer Ingelheim and Zealand Pharma's experimental drug survodutide discontinued treatment due to severe gastrointestinal side effects, a rat

Yasmin Haddad·June 8, 2026